Page last updated: 2024-10-28

hydroxyurea and Carcinoma, Intraductal, Noninfiltrating

hydroxyurea has been researched along with Carcinoma, Intraductal, Noninfiltrating in 1 studies

Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.

Research Excerpts

ExcerptRelevanceReference
"We describe a rare case of secondary breast carcinoma after chronic myeloid leukemia (CML) in a 56-year-old woman."1.46Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy. ( Bi, L; Duan, J; Fan, Z; Pan, L; Qiao, W; Wu, D; Yang, M, 2017)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pan, L1
Duan, J1
Qiao, W1
Bi, L1
Wu, D1
Fan, Z1
Yang, M1

Other Studies

1 other study available for hydroxyurea and Carcinoma, Intraductal, Noninfiltrating

ArticleYear
Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy.
    Breast cancer (Tokyo, Japan), 2017, Volume: 24, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Car

2017